Citations

Clear

1325 citation(s) found for "Mayo, Angela".

The prognostic significance of CD45 expression by clonal bone marrow plasma cells in multiple myeloma.
Morice, William G. , Timm, Michael, Lacy, Martha Q. , Hayman, Suzanne R. , Zeldenrust, Steven R., Kapoor, Prashant , Kumar, Shaji , Gonsalves, Wilson I. , Rajkumar, S. Vincent , Morice, William George , Dispenzieri, Angela , Buadi, Francis K. , Lin, Yi , Dingli, David , Leung, Nelson , Gertz, Morie A.

Mayo Clinic

Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 8577-8577

10.1200/jco.2015.33.15_suppl.8577 Get It

Interim analysis of a phase II trial of nab-paclitaxel in patients with very advanced relapsed/refractory multiple myeloma (RR-MM).
Stewart, A. Keith, Mayo, Angela, Chesi, Marta , Rosenthal, Allison , Fonseca, Rafaël , Mıkhael, Joseph , Kosiorek, Heidi , Bergsagel, P. Leif

Mayo Clinic

Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: e19537-e19537

10.1200/jco.2015.33.15_suppl.e19537 Get It

Survival trends in young patients with Waldenstrom macroglobulinemia (WM).
Vallumsetla, Nishanth, Ansell, Stephen M. , Kyle, Robert A. , Lacy, Martha Q. , Hayman, Suzanne R. , Kumar, Shaji , Kapoor, Prashant , Paludo, Jonas , Gertz, Morie A. , Go, Ronald S. , Rajkumar, S. Vincent , Buadi, Francis K. , Dispenzieri, Angela , Dingli, David , Leung, Nelson

Mayo Clinic

Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 8596-8596

10.1200/jco.2015.33.15_suppl.8596 Get It

Phase III trial of stem cell transplantation compared to melphalan and dexamethasone in the treatment of immunoglobulin light chain amyloidosis (AL).
Lacy, Martha Q. , Hayman, Suzanne R. , Kumar, Shaji , Lust, John A., Suman, V., Gertz, Morie A. , Dispenzieri, Angela , Buadi, Francis K. , Dingli, David , Leung, Nelson , Rajkumar, S. Vincent , Hogan, William J.

Mayo Clinic

Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 8595-8595

10.1200/jco.2015.33.15_suppl.8595 Get It

Comparison of different techniques to identify cardiac involvement in immunoglobulin light chain (AL) amyloidosis
Aljama, Mohammed A. , Lacy, Martha Q. , Dingli, David , Muchtar, Eli , Fonder, Amie , Hayman, Suzanne R. , Hobbs, Miriam, Warsame, Rahma , Kourelis, Taxiarchis , Hwa, Yi L. , Kapoor, Prashant , Kyle, Robert A. , Kumar, Shaji , Go, Ronald S , Muchtar, E , Dingli, David , Sidiqi, M Hasib , Dispenzieri, Angela , Gertz, Morie A. , Buadi, Francis K. , Gonsalves, Wilson I. , Leung, Nelson , Go, Ronald S. , Rajkumar, S. Vincent

Mayo Clinic

Blood Advances | April 11, 2019 | Volume: 3 | Issue: 8 | Pages: 1226-1229

10.1182/bloodadvances.2019032458 | PMID 30975646 Get It

Abstract We retrospectively reviewed the utility of N-terminal prohormone of brain natriuretic peptide (NT-proBNP) and transthoracic echocardiogram (TTE) in diagnosing cardiac involvement in patients with biopsy-proven systemic immunoglobulin light chain amyloidosis seen at the Mayo Clinic between 1 January 2006 and 30 December 2015. We analyzed 2 cohorts: patients undergoing endomyocardial biopsy for suspicion of cardiac involvement (cohort 1) and patients who had serum NT-proBNP and comprehensive echocardiographic evaluation at diagnosis (cohort 2). Of 179 patients undergoing endomyocardial biopsy (cohort 1), 173 (97%) had evidence of amyloid deposition, with 159 having NT-proBNP performed at the time of the procedure. The NT-proBNP was elevated (>300 pg/mL) in all 159 patients (sensitivity, 100%; median NT-proBNP, 4917 pg/mL; range, 355-69 541). The left ventricular ejection fraction, interventricular septal thickness, and strain rate were abnormal in 89/168 (53%), 102/64 (61%) and 92/95 (97%), respectively. Among cohort 2 (n = 342), 259 (76%) had an elevated NT-proBNP, of whom 237 (92%) had an abnormality detected on TTE. Of 83 patients with normal NT-proBNP <300 pg/mL, 27 (33%) had an abnormality on TTE (all with borderline strain rate −18% to −15%). Only 5/27 patients were considered to have possible early cardiac involvement and none had any other diagnostic or classical features of amyloidosis on TTE. The combination of NT-proBNP and comprehensive echocardiographic evaluation can diagnose cardiac amyloidosis negating the need for endomyocardial biopsy. A negative NT-proBNP rules out clinically meaningful cardiac involvement and may obviate the routine use of TTE in patients with a low clinical suspicion of cardiac amyloidosis.
Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy
Tschautscher, Marcella , Jevremović, Dragan , Rajkumar, S. Vincent , Lacy, Martha Q. , Gertz, Morie A. , Dingli, David , Hwa, Yi L. , Fonder, Amie , Hobbs, Miriam, Hayman, Suzanne R. , Zeldenrust, Steven R., Lust, John A., Russell, Stephen J. , Kapoor, Prashant , Lin, Yi , Kourelis, Taxiarchis , Warsame, Rahma , Kyle, Robert A. , Kumar, Shaji , Kaddoura, Marcella , Rajkumar, S Vincent , Gertz, Morie A , Buadi, Francis K. , Fonder, Amie L, Leung, Nelson , Gonsalves, Wilson , Kourelis, Taxiarchis , Warsame, Rahma , Russell, Stephen J , Jevremovic, Dragan , Dingli, David , Lin, Yi , Dispenzieri, Angela , Leung, Nelson , Go, Ronald S. , Gonsalves, Wilson I.

Mayo Clinic

American Journal of Hematology | April 4, 2019 | Volume: 94 | Issue: 7 | Pages: 751-756

10.1002/ajh.25481 | PMID 30945330 Get It

AbstractAchievement of a complete response has been associated with improved outcomes in patients with multiple myeloma. Recently, increasing application of minimal residual disease (MRD) assessment has shown that MRD negativity is a powerful prognostic factor for survival outcomes. We wanted to examine the impact of the polyclonal plasma cell (pPC) compartment among patients in complete response (CR) but are MRD positive. This is a retrospective cohort study where 460 myeloma patients were identified who met criteria for CR and had multicolor flow cytometry performed on the bone marrow (BM). Monoclonal and pPCs were estimated during MRD testing. Final outcomes including overall survival (OS) and time to next treatment (TTNT) were compared among the groups. The median OS for the entire cohort was not reached (95% CI; 63 mos, NR) and the median TTNT was 31 months (95% CI; 27,36). Among the MRDneg group, median TTNT was 37.6 months vs 23 months for MRDpos patients (P < .001); the median OS was not reached for either group, but there was a trend toward better survival for MRDneg patients. Among the MRDpos group, median percentage of pPCs was 65% (2.5–98.5), and those with >95% pPCs had a significantly better TTNT (NR vs 23 months; P = .02) and a trend toward better OS. We conclude that achievement of MRD negativity predicts for better response durability and trend toward improved OS and an increased proportion of pPC predicts for better outcomes within those who have residual tumor cells highlighting the importance of marrow normalization.
Postoperative Pain and 14-Day Recovery in Children Undergoing Adenotonsillectomy: Low Thermal Damage Device Versus Electrosurgery
Blake, Kathryn , Hossain, Jobayer , Chafin, Brett, Black, Angela P., Schrum, Stefanie, Josephson, Gary D. , Blake, Kathryn V

Mayo Clinic

Ear, Nose & Throat Journal | April 3, 2019 | Volume: 98 | Issue: 4 | Pages: E1-E7

10.1177/0145561319838941 | PMID 30939911 Get It

This was a randomized controlled trial of low thermal damage device versus traditional electrosurgery in children 3 to 17 years old with a clinical diagnosis of sleep disordered breathing, obstructive sleep apnea with adenotonsillar hypertrophy, or recurrent adenotonsillitis. Pain score (Wong-Baker FACES pain scale) was recorded each morning before eating, drinking, or administering pain medication for 14 days postoperatively. Seventy-five children were enrolled. There was no difference in the rate of decrease in pain scores. A significant interaction between rate of pain decrease and number of pain medication doses was present ( P < .0001). Median number of pain medication doses was greater with electrosurgery (36, range: 7-49) versus low thermal device (21, range: 2-124; P = .001). Pain scores reached 0 after a median of 7 days (95% confidence interval [CI], 5.2-8.6) for low thermal device and 9 days (95% CI, 8.0-10.0) for electrosurgery ( P = .67). One child randomized to electrosurgery was withdrawn due to hospitalization for postoperative bleed. In children, low thermal device results in significantly less pain medication used during the postoperative period than electrosurgery.
Association of Patisiran, an RNA Interference Therapeutic, With Regional Left Ventricular Myocardial Strain in Hereditary Transthyretin Amyloidosis
Minamisawa, Masatoshi, Claggett, Brian , Adams, David , Kristen, Arnt V. , Merlini, Giampaolo , Slama, Michel , Shah, Amil M. , Falk, Rodney H. , Karsten, Verena, Sweetser, Marianne T., Riese, Richard J. , Vest, John, Solomon, Scott D. , Merlini, Giampaolo , Adams, David , Shah, Amil , Dispenzieri, Angela , Falk, Rodney H , Chen, Jihong , Vest, John, Solomon, Scott David

Mayo Clinic

JAMA Cardiology | March 16, 2019 | Volume: 4 | Issue: 5 | Pages: 466

10.1001/jamacardio.2019.0849 | PMID 30878017 Get It

Combining efficacy and toxicity effect sizes from randomized clinical trials (RCTs) into an interpretable quality-adjusted effect size estimate in patients with multiple myeloma (MM).
Major, Brittny , Sloan, Jeff A. , Dispenzieri, Angela

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: e18028-e18028

10.1200/jco.2015.33.15_suppl.e18028 Get It

Clinical features, laboratory characteristics and outcomes of patients with renal versus cardiac light chain amyloidosis
Sidana, Surbhi , Tandon, Nidhi , Ramı́rez-Alvarado, Marina , Murray, David , Kourelis, Taxiarchis , Kapoor, Prashant , Gonsalves, Wilson I. , Warsame, Rahma , Lacy, Martha Q. , Kyle, Robert A. , Kumar, Shaji , Ramirez-Alvarado, Marina, Murray, David L., Kourelis, Taxiarchis V, Buadi, Francis K. , Gonsalves, Wilson , Kumar, Shaji K , Sidana, Surbhi , Ramirez-Alvarado, Marina , Gertz, Morie A. , Dispenzieri, Angela , Rajkumar, S. Vincent , Leung, Nelson

Mayo Clinic

British Journal of Haematology | March 6, 2019 | Volume: 185 | Issue: 4 | Pages: 701-707

10.1111/bjh.15832 | PMID 30836444 Get It

SummaryThis study evaluated the differences in clinical features of 1077 newly diagnosed AL amyloidosis patients with renal involvement (n = 229, 21%), both cardiac and renal involvement (n = 443, 41%) and cardiac involvement (n = 405, 38%). Significant differences in dFLC (difference in involved and uninvolved light chains) were noted (renal, both, cardiac median: 83, 234 and 349 mg/l, P < 0.001). The proportion of patients with ≥ 10% bone marrow plasma cells (BMPCs) was lowest in renal only patients: 44%, 57%, 64%, respectively, P < 0.001. In a multivariate linear regression model incorporating organ involvement type and BMPCs ≥10%, organ involvement was a significant predictor of dFLC (P < 0.001). Median overall survival (OS) across the three groups was 83 vs. 19 vs. 16 months (P < 0.001) in patients not undergoing transplant and 5‐year OS in patients undergoing transplant was 90% vs. 75% vs. 64% (P = 0.007), respectively. In conclusion, renal involvement alone or renal + cardiac involvement in AL amyloidosis is associated with lower circulating light chain burden, which cannot be fully explained by BMPC burden alone. Increased sensitivity of the kidney to light chains, given significant interactions with the renal tubular system and secretion of modified light chain products may play a role in pathogenesis of renal AL amyloidosis and warrants further investigation.